1. Introduction {#sec1}
===============

Cardiovascular disease (CVD) is the leading cause of death for both men and women worldwide \[[@B1]\]. Acute coronary syndrome (ACS), a major clinical manifestation of atherothrombosis, refers to a wide spectrum of clinical presentations, such as ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTE-ACS), and increases with age, and the outcomes of ACS in elderly patients are generally worse than those in young patients \[[@B2]\]. Almost one out of every two patients hospitalized for ACS is over 75 years of age \[[@B3], [@B4]\], and the in-hospital mortality due to ACS ranges from 4% to10% \[[@B4], [@B5]\].

Women account for approximately 30% of patients presenting with ACS \[[@B4], [@B6]\] and have long been described as being "older and sicker" than their male counterparts \[[@B7]\]. In particular, significant sex-related differences exist in ACS presentation, management, and outcomes \[[@B7]\]. A large contemporary registry study in China demonstrated that women hospitalized for ACS received acute treatments and secondary prevention less frequently and had a higher in-hospital mortality than men due to poor clinical profiles and little evidence for acute treatments \[[@B4]\]. To date, little is known about the sex-related differences in elderly patients with ACS.

The Italian Elderly ACS study included patients with NSTE-ACS and ≥75 years of age and showed that women had poor 1-year primary outcomes, including death, nonfatal myocardial infarction, disabling stroke, cardiac rehospitalization, and severe bleeding \[[@B8]\]. According to a nationwide registry study in the Netherlands, the relation between sex and mortality appeared to be age-dependent, with increased mortality in women at a young age and decreased mortality in women at an advanced age \[[@B9]\]. It is still unclear whether these differences can be solely explained by sex or by other factors such as age, extent or impact of risk factors, clinical presentation, and treatment strategies. Therefore, this study focused on patients with ACS and ≥75 years and aimed to investigate the sex differences in the clinical characteristics, in-hospital management, adverse events, and 1-year mortality among those patients.

2. Methods {#sec2}
==========

2.1. Study Design and Patients {#sec2.1}
------------------------------

This retrospective single-center study included 711 consecutive patients with ACS and ≥75 years of age who were hospitalized in our department between January 2013 and December 2017. Only patients who were initially admitted to our center were included; those who were transferred from other centers were excluded. The diagnostic criteria for ACS were based on the presence of chest pain or discomfort, electrocardiogram (ECG) findings, and myocardial injury biomarker measurements. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Human Research Committee of the Second Xiangya Hospital of Central South University. The need for individual consent was waived by the committee.

2.2. Definitions and Endpoints {#sec2.2}
------------------------------

ACS was defined in accordance with the guidelines published by the American College of Cardiology for the diagnosis and management of patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTE-ACS) \[[@B10], [@B11]\]. Renal insufficiency (CKD ≥3) was defined as an estimated glomerular filtration rate (eGFR) \< 60 mL/min per 1.73 m^2^. In our study, severe heart failure indicated class III-IV heart failure, according to the Killip or New York Heart Association classification system. Readmission was defined as any readmission after discharge. Stroke was defined as the sudden onset of focal neurological deficit resulting from either cerebral infarction or hemorrhage. According to the Bleeding Academic Research Consortium (BARC) criteria, BARC types 2 and 3 were included as in-hospital bleeding events \[[@B12]\]. A BARC type 2 event was defined as clinically overt hemorrhage requiring medical attention, whereas a BARC type 3 event was defined as bleeding, including gastrointestinal bleeding, respiratory bleeding, and genitourinary bleeding, with a hemoglobin decrease of at least 3 g/dl, requiring transfusion or surgical intervention.

The primary outcome was 1-year all-cause mortality. The secondary outcomes included the rates of revascularization, readmission, and stroke over 1 year of follow-up.

2.3. Data Collection {#sec2.3}
--------------------

The following data were collected: body weight, height, and body mass index (BMI) during hospitalization, diabetes, atrial fibrillation, chronic kidney disease, history of chest pain, history of CVD treatment, smoking, laboratory parameters, length of hospital stay, demographic characteristics, medication, in-hospital management, and adverse events. The following biochemical parameters were also extracted from the medical charts: hemoglobin, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, and glycated hemoglobin (HbA1c).

2.4. Follow-Up {#sec2.4}
--------------

In-hospital outcomes were ascertained by a hospital chart review. After discharge, participant follow-up was carried out by means of outpatient visits and telephone calls for up to one year.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Categorical variables were presented as numbers (percentages) and compared using the Pearson chi-squared tests or Fisher\'s exact test. Continuous variables were presented as mean ± SD and compared using Student\'s *t*-test if the data were normally distributed. Nonnormally distributed continuous variables were presented as medians (interquartile ranges) and compared using nonparametric tests. Odds ratios (ORs) were presented with 95% confidence intervals (CIs). Univariable factor logistic regression was used to analyze the risk factors associated with 1-year all-cause mortality. A multivariable logistic regression analysis was used to define the independent determinants of 1-year all-cause mortality after adjusting for comorbidities, presentation, and clinical profiles. Meaningful factors, defined by the univariable *p* \< 0.05, including age (Model 1); hypertension; current smoking; severe heart failure (Model 2); hemoglobin, platelet, total cholesterol, HDL-C, LDL-C, creatinine, and serum uric acid levels (Model 3), were included in the multivariable logistic regression analysis. A two-tailed *p*-value \<0.05 indicated statistical significance. All statistical analyses were conducted using SPSS 22.0 (IBM, Armonk, NY, USA).

3. Results {#sec3}
==========

3.1. Characteristics of the Patients {#sec3.1}
------------------------------------

There were 273 (38.4%) women and 438 (61.6%) men. They were 75--94 years of age, and the age distribution was similar between women and men (78 \[76--81\] vs. 78 \[76--80\], *p*=0.381).

3.2. Characteristics of the Patients according to Sex {#sec3.2}
-----------------------------------------------------

The baseline characteristics of each group are listed in [Table 1](#tab1){ref-type="table"}. Women had a higher prevalence of traditional risk factors for CVD, including hypertension (79.5% vs. 72.8%, *p*=0.050), diabetes mellitus (35.2% vs. 26.5%, *p*=0.014), and hyperuricemia (39.9% vs. 32.4%, *p*=0.042), but a lower prevalence of current smoking (5.4% vs. 56.5%, *p* \< 0.001) than men. The prevalence of severe heart failure on admission (56.8% vs. 46.0%, *p*=0.005) and NSTE-ACS (79.5% vs. 71.2%, *p*=0.014) was significantly higher, while STEMI (20.5% vs. 28.8%, *p*=0.014) was less frequent in women than in men. Platelet counts (202.9 ± 64.9 vs. 174.3 ± 61.4, *p* \< 0.001), total cholesterol (4.1 ± 1.0 vs. 3.8 ± 0.9, *p* \< 0.001), LDL-C (2.4 ± 0.9 vs. 2.2 ± 0.8, *p*=0.002), and HDL-C (1.1 ± 0.3 vs. 1.0 ± 0.3, *p*=0.002) were significantly higher, whereas hemoglobin levels (110.4 ± 18.3 vs. 121.8 ± 20.2, *p* \< 0.001), creatinine levels (89.9 ± 54.1 vs. 124.4 ± 98.6, *p* \< 0.001), and serum uric acid (349.2 ± 119.1 vs. 381.4 ± 110.1, *p* \< 0.001) were significantly lower in women than in men. Regarding in-hospital management, the coronary revascularization rate was significantly lower in women than in men (30.0% vs. 39.7%, *p*=0.022), while the medication rate and rate of intra-aortic balloon pump (IABP) use were similar between the two groups. There were no differences in in-hospital adverse events. A total of 135 patients died (19.0%), and the 1-year mortality rate was significantly lower in women than in men (14.7% vs. 21.7%, *p*=0.020). The percentages of rehospitalization, revascularization, stroke, and bleeding after discharge were similar between the two groups.

3.3. Differences between Women and Men according to ACS Type {#sec3.3}
------------------------------------------------------------

The results of the subgroup (NSTE-ACS and STEMI) comparisons are shown in [Table 2](#tab2){ref-type="table"}. There were 182 (25.8%) patients with STEMI and 529 (74.2%) with NSTE-ACS. Among the 256 (36%) patients who underwent coronary revascularization, 93 (51.1%) were STEMI patients, and 163 (30.8%) were NSTE-ACS patients. Sex-related differences, including the prevalence of current smoking, and hemoglobin, platelet, total cholesterol, LDL-C, creatinine, and serum uric acid levels were still observed in both STEMI and NSTE-ACS subgroups. In the NSTE-ACS subgroup, the rates of hyperuricemia (41.9% vs. 31.4%, *p*=0.013), severe heart dysfunction on admission (60.8% vs. 47.9%, *p*=0.003), high HDL-C (1.1 ± 0.3 vs. 1.0 ± 0.3, *p*=0.002), and the use of proton pump inhibitors (PPIs) (81.2% vs. 72.6%, *p*=0.024) were significantly higher, while the coronary revascularization rate (22.6% vs. 36.5%, *p*=0.002) was lower in women than in men, but these differences were not observed in the STEMI subgroup. In patients with STEMI, the rate of diabetes mellitus (48.2% vs. 19.8%, *p* \< 0.001) was higher in women than in men and 1-year mortality (19.6% vs. 38.1%, *p*=0.014) was lower.

3.4. Multivariable Analyses between Women and Men {#sec3.4}
-------------------------------------------------

To evaluate whether the residual sex difference in mortality could be explained by disparities in the risk factors, we examined the independent determinants of 1-year all-cause mortality. As shown in [Table 3](#tab3){ref-type="table"}, female patients had a significantly lower unadjusted risk of death (unadjusted OR = 0.620, 95% CI 0.413--0.929, *p*=0.021) than male patients. The multivariable logistic regression analysis showed similar results (OR = 0.597, 95% CI 0.397--0.900, *p*=0.014) after adjusting for age (Model 1). Additional variables included diabetes mellitus, hypertension, current smoking, and severe heart failure (Model 2) and hemoglobin, platelet, total cholesterol, HDL-C, LDL-C, creatinine, and serum uric acid levels (Model 3). The same associations were observed in Model 2 (OR = 0.531, 95% CI 0.347--0.811, *p*=0.003) and Model 3 (OR = 0.565, 95% CI 0.351--0.908, *p*=0.018). Similar results were observed in elderly patients with STEMI but not in elderly patients with NSTE-ACS.

Regarding the adjustment variables in Model 3, in all patients, age (OR = 1.08, 95% CI: 1.02--1.15, *p*=0.010), severe heart failure (OR = 1.77, 95% CI: 1.14--2.75, *p*=0.011), PLT levels (OR = 1.004, 95% CI: 1.001--1.007, *p*=0.018), and creatinine levels (OR = 1.005, 95% CI: 1.003--1.007, *p* \< 0.001) were associated with mortality, along with sex (OR = 0.57, 95% CI: 0.35--0.91, *p*=0.018). In patients with STEMI, severe heart failure (OR = 3.84, 95% CI: 1.89--7.78, *p* \< 0.001) was associated with mortality, along with sex (OR = 0.42, 95% CI: 0.18--0.94, *p*=0.035). In patients with NSTE-ACS, age (OR = 1.09, 95% CI: 1.01--1.18, *p*=0.033), hemoglobin (OR = 0.98, 95% CI: 0.97--1.00, *p*=0.027), LDL (OR = 1.49, 95% CI: 1.07--2.08, *p*=0.018), and creatinine (OR = 1.004, 95% CI: 1.002--1.007, *p*=0.001) were associated with mortality.

4. Discussion {#sec4}
=============

The main findings of the present study are as follows: (1) elderly women had more comorbidities and were more likely to present with NSTE-ACS than men in the total ACS cohort; (2) in women with NSTE-ACS, the prevalence of severe heart failure on admission was higher, and they underwent coronary revascularization less often than men, but in-hospital adverse events and 1-year mortality were similar between women and men; (3) in STEMI patients, there were no differences in the in-hospital treatments and in-hospital adverse events between women and men, but women had lower 1-year mortality than men; and (4) female sex was a protective factor for 1-year mortality in all populations, especially in patients with STEMI.

Although traditional atherosclerotic disease risk factors are important for both men and women with ACS, some factors accumulated more often in female patients. In the present study, women had higher rates of traditional risk factors, including hypertension, diabetes, hyperuricemia, elevated LDL-C, and severe heart failure, than men. In contrast, men were more likely to be smokers and have elevated creatinine levels. Notably, these differences were similar across both types of ACS (STEMI and NSTE-ACS). These risk factor distribution patterns have been confirmed by other studies in the whole populations \[[@B7]\] and in elderly patients \[[@B4], [@B9]\]. In addition, women have sex-specific risk factors, such as pregnancy and menopause \[[@B7], [@B13]\]. It is accepted that the cardiovascular risk profile of women worsens during postmenopause, and the prevalence of coronary artery disease (CAD) steeply increases with age thereafter. We also observed that among the elderly patients with ACS, women were more likely to present with NSTE-ACS than men, whereas men presented with STEMI more often than women. This finding is in agreement with data derived from the Improving Care for Cardiovascular Disease in China (CCC) Project, in that the prevalence of STEMI was significantly lower in women than in men, and women were more likely to present with NSTE-ACS compared to their male counterparts \[[@B4]\]. An increased burden of plaque erosion, coronary vasospasm, spontaneous coronary artery dissection, and stress-related cardiomyopathy in women might partly be related to the observed phenomenon \[[@B7]\].

In terms of in-hospital management among patients with NSTE-ACS, there were no differences between women and men, except for the use of PPIs. We believe that the use of PPIs occurred more often in women than in men, which could be explained by the increased bleeding risk in women with ACS \[[@B8], [@B14], [@B15]\]. Nevertheless, no difference was observed regarding in-hospital bleeding in the present study; the use of PPIs might partly contribute to this finding. In the present study, we observed a lower coronary revascularization rate in women hospitalized for NSTE-ACS than in men. This result is in line with data from the CCC project, which showed that eligible women with NSTE-ACS were less likely to undergo timely percutaneous coronary intervention (PCI) than men with NSTE-ACS (30.5% vs. 34.2%, *p* \< 0.001) \[[@B4]\]. We believe that the fear of complications associated with invasive treatments might, in part, explain this finding because women, especially older women, might be considered too fragile to undergo aggressive treatments. A surprising finding in our study was the similar in-hospital clinical outcomes between women and men, despite fewer PCI carried out in women. This finding was in contrast with a previous report that showed that women with NSTE-ACS had higher crude in-hospital mortality rates than men with NSTE-ACS \[[@B4]\]. Because our cohort included only patients of ≥75 years of age, the above difference might originate from the different age groups. In addition, a recent report confirmed that women with NSTE-ACS ≥70 years of age had better outcomes than those \<70 years \[[@B8]\]. Another study using data from the National Inpatient Sample (NIS) database in the United States indicated that women had lower risk-adjusted in-hospital mortality than men after accounting for differences in age and comorbidities \[[@B16]\]. These findings suggested that the relation between sex and mortality was age-dependent, with increased mortality in women at a young age and decreased mortality in women at an advanced age.

Among the patients with STEMI, there were no differences regarding in-hospital treatments and in-hospital adverse events between women and men, but women had better 1-year outcomes than men in the present study. Some studies demonstrated increased rates of mortality among women, some studies indicated no difference, and other studies showed lower rates of mortality in women than in men \[[@B17]\]. These controversial results may be explained by potential interactions between age and sex; significant differences in in-hospital mortality rates between women and men with STEMI were demonstrated when the cohort was stratified by age groups (\<55 years, 55--64 years, and \>75 years) \[[@B4]\]. Younger age was associated with higher 30-day mortality rates in women with STEMI, but this difference decreased after age 60 and was no longer observed in elderly women \[[@B18]\]. In fact, mortality in elderly women was lower than that in age-matched men, as shown by previous studies \[[@B19], [@B20]\]; this result was further confirmed by the Netherlands National Trial Register, which showed that excess mortality in women mostly occurred in young patients with STEMI, while older women had a better outcome than men of the same age \[[@B9]\]. These findings suggest that there is an age-dependent relationship among the outcomes between male and female patients with STEMI. Our results show that elderly female patients with STEMI have lower 1-year mortality than elderly male patients with STEMI.

Previous studies have shown that sex differences in early mortality after ACS could be largely explained by the clinical differences at presentation \[[@B21], [@B22]\]. To evaluate whether the sex differences associated with 1-year mortality could be explained by disparities in clinical characteristics, we adjusted for comorbidities, presentation, and clinical profiles. After adjusting for age (Model 1); age, diabetes mellitus, hypertension, current smoking, and severe heart failure (Model 2); and hemoglobin, platelet counts, total cholesterol, HDL-C, LDL-C, creatinine, and serum uric acid (Model 3), the female sex was consistently shown as an independent protective factor for 1-year mortality in the whole cohort, especially among patients with STEMI. Nevertheless, a delay in presentation \[[@B1], [@B4], [@B23]\] and angiographic severity of coronary lesions \[[@B17]\], which may also contribute to the sex difference in mortality after ACS, were not adjusted in the present study. In addition, a previous study indicated that the more favorable mortality rate in older women could be attributed to the shorter exposure to obstructive coronary disease and longer life expectancy in women than in men \[[@B18]\]. In all patients, sex, age, severe heart failure, PLT, and creatinine were all independently associated with mortality. In patients with STEMI, only sex and severe heart failure were independently associated with mortality. Since all patients were menopausal, the differences cannot be attributed to estrogens, and other factors are also involved in the mortality risk. In patients with NSTE-ACS, age, hemoglobin, LDL, and creatinine were independently associated with mortality, but not sex. Therefore, in NSTE-ACS, other traditional risk factors for mortality play more important roles in the risk of mortality. Nevertheless, the mechanism for the sex disparity in 1-year mortality, especially in elderly patients with STEMI, still needs to be further investigated in future studies.

5. Limitations {#sec5}
==============

This study has some limitations. First, this was a single-center experience and included a small number of patients. Second, residual measured and unmeasured confounding factors, including changes in ECG parameters, might have contributed to some of these findings but were not included in the regression model. Third, the data were based on the routine clinical parameters measured in the management of ACS, which do not include sexual hormone levels. Finally, the details of the procedural characteristics, especially the time intervals for STEMI and angiographic severity of coronary lesions, are important in view of the previously described sex differences in the literature, but these factors were not analyzed in this study.

6. Conclusion {#sec6}
=============

Our study showed that elderly women with ACS had more comorbidities and were more likely to present with NSTE-ACS than men in the total cohort, similar to other studies. A surprising finding was the better 1-year outcome in elderly women with STEMI than in elderly men with STEMI, while in-hospital and 1-year outcomes were similar between elderly women and men with NSTE-ACS. It is worth noting that the female sex was an independent protective factor for 1-year mortality in the whole ACS cohort, especially in patients with STEMI.
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Differences between women and men.

                                            Women (*n* = 273)       Men (*n* = 438)          *p*
  ----------------------------------------- ----------------------- ------------------------ ---------
  Demographics and medical history                                                            
   Age, yrs (median, IQR)                   78 (76--81)             78 (76--80)              0.381
   Body mass index (median, IQR)            22.7 (20.6--25.4)       23.1 (20.9--25.4)        0.427
   Diabetes mellitus, no. (%)               96 (35.2)               116 (26.5)               0.014
   Hypertension, no. (%)                    217 (79.5)              319 (72.8)               0.050
   Atrial fibrillation, no. (%)             30 (11.2)               53 (12.3)                0.656
   CKD ≥ 3                                  13 (4.8)                26 (5.9)                 0.506
   Stroke, no. (%)                          32 (11.9)               71 (16.5)                0.098
   Previous chest pain, no. (%)             181 (67.5)              286 (66.2)               0.716
   Previous PCI, no. (%)                    36 (13.5)               78 (18.1)                0.112
   Previous CABG, no. (%)                   3 (1.1)                 10 (2.3)                 0.255
   Current smoking, no. (%)                 14 (5.4)                239 (56.5)               \<0.001
  Clinical presentation                                                                       
   Hyperuricemia, no. (%)                   109 (39.9)              142 (32.4)               0.042
   Severe heart failure, no. (%)            155 (56.8)              201 (46.0)               0.005
   STEMI, no. (%)                           56 (20.5)               126 (28.8)               0.014
   NSTE-ACS, no. (%)                        217 (79.5)              312 (71.2)               0.014
  Laboratory data                                                                             
   WBC, 10^9^/L (mean ± SD)                 7.4 ± 3.3               7.2 ± 3.2                0.568
   Hemoglobin, g/L (mean ± SD)              110.4 ± 18.3            121.8 ± 20.2             \<0.001
   Platelets, 10^9^/L (mean ± SD)           202.9 ± 64.9            174.3 ± 61.4             \<0.001
   Fasting glucose, mmol/l (median, IQR)    6.0 (4.9--7.6)          5.7 (4.8--7.1)           0.181
   HbA1C, % (median, IQR)                   6.7 (6.0--7.4)          6.1 (5.6--6.5)           0.005
   ALT, u/l (median, IQR)                   17.5 (11.7--28.3)       19.9 (13.6--33.5)        0.012
   AST, u/l (median, IQR)                   22.6 (17.1--39.5)       22.6 (17.8--49.9)        0.579
   Albumin, g/L (mean ± SD)                 35.1 ± 4.5              35.1 ± 4.1               0.902
   Triglycerides, mmol/l (mean ± SD)        1.6 ± 1.0               1.6 ± 4.2                0.960
   Total cholesterol, mmol/l (mean ± SD)    4.1 ± 1.0               3.8 ± 0.9                \<0.001
   HDL-C, mmol/l (mean ± SD)                1.1 ± 0.3               1.0 ± 0.3                0.002
   LDL-C, mmol/l (mean ± SD)                2.4 ± 0.9               2.2 ± 0.8                0.002
   Creatinine, *μ*mmol/l (mean ± SD)        89.9 ± 54.1             124.4 ± 98.6             \<0.001
   Serum uric acid, *μ*mmol/l (mean ± SD)   349.2 ± 119.1           381.4 ± 110.1            \<0.001
   PT, sec (mean ± SD)                      13.7 ± 4.3              13.5 ± 2.8               0.674
   APTT, sec (mean ± SD)                    39.5 ± 14.4             41.4 ± 22.2              0.562
   CK-Mb, u/l (mean ± SD)                   35.0 ± 71.4             44.3 ± 119.0             0.266
   TnT, pg/ml (median, IQR)                 19.3 (9.7--603.3)       33.2 (12.3--1461.0)      0.141
   hs-CRP, mg/l (median, IQR)               4.3 (1.3--23.2)         5.1 (1.4--20.2)          0.849
   NT-proBNP, pg/ml (median, IQR)           935.9 (290.4--3082.5)   1337.0 (394.9--3737.7)   0.067
   EF, % (mean ± SD)                        53 ± 10.4               53 ± 10.9                0.460
  In-hospital management                                                                      
   Aspirin, no. (%)                         227 (83.2)              376 (86.2)               0.262
   Clopidogrel, no. (%)                     234 (86.0)              391 (89.5)               0.168
   ACEI/ARB, no. (%)                        168 (61.5)              268 (61.2)               0.925
   Beta blocker, no. (%)                    206 (75.5)              306 (69.9)               0.106
   Statin, no. (%)                          265 (97.8)              422 (96.3)               0.283
   Diuretic, no. (%)                        128 (47.6)              210 (48.6)               0.791
   PPI, no. (%)                             227 (84.4)              340 (78.7)               0.063
   IABP, no. (%)                            7 (2.6)                 18 (4.2)                 0.255
   Revascularization                        82 (30.0)               174 (39.7)               0.022
  In-hospital events                                                                          
   Heart failure, no. (%)                   42 (15.7)               77 (17.9)                0.458
   Bleeding, no. (%)                        22 (8.2)                39 (9.1)                 0.706
   Ventricular tachycardia, no. (%)         23 (8.6)                36 (8.3)                 0.920
   Stroke, no. (%)                          5 (1.9)                 2 (0.5)                  0.071
   Death, no. (%)                           4 (3.5)                 8 (4.4)                  0.693
  One-year follow-up                                                                          
   Revascularization                        4 (1.6)                 7 (1.9)                  0.801
   Readmission, no. (%)                     96 (36.9)               159 (39.9)               0.436
   Stroke, no. (%)                          13 (5.2)                18 (4.8)                 0.827
   Death, no. (%)                           40 (14.7)               95 (21.7)                0.020

STEMI: ST-segment elevation myocardial infarction; NSTE-ACS: non-ST-elevation acute coronary syndrome; WBC: white blood cell; ALT: glutamic-pyruvic transaminase; AST: glutamic-oxaloacetic transaminase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; PT: prothrombin time; APTT: activated partial thromboplastin time; ACEI/ARB: angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; PPI: proton pump inhibitor; IABP: intra-aortic balloon pump; CKD: chronic kidney disease; and CKD ≥ 3: estimated glomerular filtration rate (eGFR) \< 60 mL/min per 1.73 m^2^.

###### 

Differences between women and men according to ACS type.

                                            NSTE-ACS                STEMI                                                                                 
  ----------------------------------------- ----------------------- ----------------------- --------- ------------------------- ------------------------- ---------
  Demographics and medical history                                                                                                                         
   Age, yrs (median, IQR)                   78 (76--81)             78 (76--80)             0.085     77 (76--80)               78 (76--81)               0.218
   Body mass index, (median, IQR)           22.7 (20.5--25.4)       23.2 (20.9--25.5)       0.275     22.3 (20.7--25.3)         22.3 (19.8--24.6)         0.703
   Diabetes mellitus, no. (%)               69 (31.8)               91 (29.2)               0.517     27 (48.2)                 25 (19.8)                 \<0.001
   Hypertension, no. (%)                    182 (83.7)              248 (79.5)              0.204     35 (62.5)                 71 (56.3)                 0.437
   Atrial fibrillation, no. (%)             19 (8.9)                35 (11.4)               0.362     11 (19.6)                 18 (14.4)                 0.374
   CKD ≥ 3                                  9 (4.2)                 14 (4.5)                0.853     4 (7.1)                   12 (9.5)                  0.601
   Stroke, no. (%)                          25 (11.8)               54 (17.6)               0.068     7 (12.5)                  17 (13.7)                 0.825
   Previous chest pain, no. (%)             148 (69.8)              219 (71.3)              0.708     33 (58.9)                 67 (53.6)                 0.505
   Previous PCI, no. (%)                    32 (15.1)               69 (22.5)               0.037     4 (7.3)                   9 (7.2)                   0.986
   Previous CABG, no. (%)                   3 (1.4)                 10 (3.3)                0.187     0 (0)                     0 (0)                     NA
   Current smoking, no. (%)                 7 (3.4)                 166 (55.5)              \<0.001   7 (12.5)                  73 (58.9)                 \<0.001
  Clinical presentation                                                                                                                                    
   Hyperuricemia, no. (%)                   91 (41.9)               98 (31.4)               0.013     18 (32.1)                 44 (34.9)                 0.715
   Severe heart failure, no. (%)            132 (60.8)              149 (47.9)              0.003     23 (41.1)                 52 (41.3)                 0.980
  Laboratory data                                                                                                                                          
   WBC, 10^9^/L (mean ± SD)                 6.8 ± 2.6               6.5 ± 2.4               0.076     9.4 ± 4.6                 9.1 ± 4.0                 0.752
   Hemoglobin, g/L (mean ± SD)              110.3 ± 19.0            122.4 ± 20.2            \<0.001   110.9 ± 15.4              120.3 ± 20.1              0.001
   Platelets, 10^9^/L (mean ± SD)           200.3 ± 62.3            171.0 ± 60.0            \<0.001   212.7 ± 73.7              182.5 ± 64.2              0.009
   Fasting glucose, mmol/l (median, IQR)    5.9 (4.9--6.9)          5.6 (4.8--6.8)          0.083     6.8 (4.9--8.2)            6.3 (5.3--7.7)            0.873
   HbA1C, % (median, IQR)                   6.5 (5.9--7.0)          6.2 (5.7--6.8)          0.115     7.0 (6.1--7.7)            5.8 (5.5--6.1)            0.035
   ALT, u/l (median, IQR)                   16.0 (10.9--22.9)       18.0 (12.4--27.8)       0.006     33.0 (20.7--48.5)         31.7 (16.7--58.8)         0.533
   AST, u/l (median, IQR)                   21.0 (16.2--26.9)       19.8 (16.9--27.2)       0.813     76.0 (25.7--286.4)        67.3 (28.7--187.7)        0.759
   Albumin, g/L (mean ± SD)                 35.7 ± 4.5              35.8 ± 3.8              0.785     32.9 ± 3.5                33.4 ± 4.1                0.494
   Triglycerides, mmol/l (mean ± SD)        1.6 ± 1.1               1.7 ± 5.0               0.725     1.6 ± 0.8                 1.3 ± 0.9                 0.009
   Total cholesterol, mmol/l (mean ± SD)    4.0 ± 1.0               3.7 ± 0.9               \<0.001   4.4 ± 1.1                 3.9 ± 0.9                 0.002
   HDL-cholesterol, mmol/l (mean ± SD)      1.1 ± 0.3               1.0 ± 0.3               0.002     1.1 ± 0.3                 1.0 ± 0.3                 0.373
   LDL-cholesterol, mmol/l (mean ± SD)      2.3 ± 0.9               2.2 ± 0.8               0.018     2.7 ± 1.0                 2.3 ± 0.8                 0.005
   Creatinine, *μ*mmol/l (mean ± SD)        91.3 ± 53.7             124.7 ± 109.1           \<0.001   84.3 ± 56.0               123.4 ± 66.6              \<0.001
   Serum uric acid, *μ*mmol/l (mean ± SD)   352.6 ± 121.5           380.8 ± 106.9           0.005     336.6 ± 109.1             383.0 ± 118.1             0.013
   PT, sec (mean ± SD)                      13.7 ± 4.6              13.2 ± 3.0              0.367     13.6 ± 1.8                14.4 ± 1.7                0.164
   APTT, sec (mean ± SD)                    38.3 ± 10.4             39.4 ± 21.3             0.741     45.8 ± 27.5               47.9 ± 24.9               0.830
   CK-Mb, u/l (mean ± SD)                   19.6 ± 34.8             27.1 ± 91.3             0.280     91.0 ± 124.5              82.4 ± 158.2              0.725
   TnT, pg/ml (median, IQR)                 15.8 (8.9--49.1)        16.4 (10.8--66.4)       0.380     3092.5 (2437.8--4858.0)   2117.0 (1057.9--4761.0)   0.288
   hs-CRP, mg/l (median, IQR)               2.7 (1.1--15.1)         3.4 (1.1--12.9)         0.813     24.5 (12.1--44.8)         14.9 (4.4--55.7)          0.328
   NT-proBNP, pg/ml (median, IQR)           644.5 (225.5--2074.6)   755.3 (256.7--2273.2)   0.458     2751.7 (1418.2--6079.7)   3387.9 (1561.7--7932.8)   0.268
   EF, % (mean ± SD)                        55.3 ± 10.1             55.1 ± 10.1             0.862     47.9 ± 9.6                48.0 ± 11.5               0.961
  In-hospital management                                                                                                                                   
   Aspirin, no. (%)                         174 (80.2)              261 (83.9)              0.267     53 (94.6)                 115 (92.0)                0.524
   Clopidogrel, no. (%)                     183 (84.7)              273 (87.8)              0.312     51 (91.1)                 118 (93.7)                0.533
   ACEI/ARB, no. (%)                        129 (59.4)              190 (60.9)              0.737     39 (69.6)                 78 (61.9)                 0.315
   Beta blocker, no. (%)                    167 (77.0)              218 (69.9)              0.072     39 (69.6)                 88 (69.8)                 0.979
   Statin, no. (%)                          210 (97.7)              298 (95.5)              0.191     55 (98.2)                 124 (98.4)                0.923
   Diuretic, no. (%)                        93 (43.7)               124 (40.4)              0.457     35 (62.5)                 86 (68.8)                 0.405
   PPI, no. (%)                             173 (81.2)              223 (72.6)              0.024     54 (96.4)                 117 (93.6)                0.441
   IABP, no. (%)                            1 (0.5)                 8 (2.6)                 0.089     6 (10.7)                  10 (8.3)                  0.609
   Revascularization                        49 (22.6)               114 (36.5)              0.002     33 (41.1)                 60 (47.6)                 0.159
  In-hospital events                                                                                                                                       
   Heart failure, no. (%)                   25 (11.8)               29 (9.5)                0.404     17 (30.9)                 48 (38.4)                 0.335
   Bleeding, no. (%)                        14 (6.6)                17 (5.6)                0.618     8 (14.3)                  22 (17.6)                 0.579
   Ventricular tachycardia, no. (%)         16 (7.5)                19 (6.2)                0.554     7 (12.5)                  17 (13.6)                 0.840
   Stroke, no. (%)                          3 (1.4)                 1 (0.3)                 0.310     2 (3.6)                   1 (0.8)                   0.177
   Death, no. (%)                           2 (2.2)                 4 (3.0)                 0.719     2 (8.7)                   4 (8.7)                   1.000
  One-year follow-up                                                                                                                                       
   Revascularization                        4 (2.0)                 6 (2.2)                 0.891     0 (0.0)                   1 (1.1)                   0.480
   Readmission, no. (%)                     78 (37.3)               119 (40.5)              0.475     18 (35.3)                 40 (38.5)                 0.702
   Stroke, no. (%)                          10 (4.9)                16 (5.7)                0.698     3 (6.4)                   2 (2.1)                   0.193
   Death, no. (%)                           29 (13.4)               47 (15.1)               0.583     11 (19.6)                 48 (38.1)                 0.014

###### 

Multivariable logistic regression analysis of one-year all-cause mortality.

                          Unadjusted   Model 1      Model 2   Model 3                                                                             
  ----------------------- ------------ ------------ --------- --------- ------------ --------- ------ ------------ ------- ------- -------------- ---------
  Total                                                                                                                                            
   Women vs. men          0.62         0.41--0.93   0.021     0.60      0.40--0.90   0.014     0.53   0.35--0.81   0.003   0.57    0.35--0.91     0.018
   Age                    ---          ---          ---       1.10      1.04--1.16   0.001     1.09   1.03--1.15   0.003   1.08    1.02--1.15     0.010
   Severe heart failure   ---          ---          ---       ---       ---          ---       ---    ---          ---     1.77    1.14--2.75     0.011
   PLT                    ---          ---          ---       ---       ---          ---       ---    ---          ---     1.004   1.001--1.007   0.018
   Creatinine             ---          ---          ---       ---       ---          ---       ---    ---          ---     1.005   1.003--1.007   \<0.001
  STEMI                                                                                                                                            
   Women vs. men          0.40         0.19--0.84   0.016     0.40      0.19--0.84   0.016     0.36   0.17--0.79   0.011   0.42    0.18--0.94     0.035
   Severe heart failure   ---          ---          ---       ---       ---          ---       3.21   1.66--6.22   0.001   3.84    1.89--7.78     \<0.001
  NSTE-ACS                                                                                                                                         
   Women vs. men          0.87         0.53--1.43   0.584     0.81      0.49--1.34   0.405     0.72   0.43--1.23   0.230   0.71    0.38--1.33     0.283
   Age                    ---          ---          ---       1.13      1.05--1.20   \<0.001   1.10   1.02--1.18   0.009   1.09    1.01--1.18     0.033
   Severe heart failure   ---          ---          ---       ---       ---          ---       1.79   1.05--3.07   0.033   ---     ---            ---
   Hemoglobin             ---          ---          ---       ---       ---          ---       ---    ---          ---     0.98    0.97--1.00     0.027
   LDL                    ---          ---          ---       ---       ---          ---       ---    ---          ---     1.49    1.07--2.08     0.018
   Creatinine             ---          ---          ---       ---       ---          ---       ---    ---          ---     1.004   1.002--1.007   0.001
   Serum uric acid        ---          ---          ---       ---       ---          ---       ---    ---          ---     1.002   1.000--1.004   0.090

Data are expressed as OR ± 95% CIs (reported in parentheses) as assessed by univariate (unadjusted) or multivariate logistic regression analyses. Other covariates included in multivariate logistic regression models were as follows: Model 1: age; Model 2: age, diabetes mellitus, hypertension, current smoking, and severe heart failure; Model 3: adjustment for variables included age, diabetes mellitus, hypertension, current smoking, severe heart failure, hemoglobin, PLT, total cholesterol, HDL-C, LDL-C, creatinine level, and serum uric acid. The adjustment parameters which were statistically significant were shown.
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